• Trials to Test Potential for Immunotherapy Technology

News & Views

Trials to Test Potential for Immunotherapy Technology

Sydney-based Immutep Ltd, developers of immunotherapy treatments for cancer and autoimmune diseases, is to receive a milestone payment from GSK of GB £4 million (approx AU $7.39 million) related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis. 

GSK2831781 is derived from Immutep’s IMP731 antibody, a depleting anti-LAG antibody technology that was exclusively licensed to GSK. Under the terms of the agreement, the Australian biotech is eligible to receive up to GB £64 million (approx AU $118.17 million) in developmental milestone payments as well as single-digit tiered royalties, if commercialisation stages are reached. GSK is responsible for all costs associated with the clinical development and the commercialisation process.

Immutep CEO Marc Voigt, said: “It is very encouraging to see GSK advancing their product candidate in a phase II clinical trial for ulcerative colitis, further validating LAG-3 as a potential target for therapeutics in autoimmune diseases. These partner milestone payments are an important source of non-dilutive funding to the company and this capital will be deployed to further advance our extensive development programs.”


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

View all events